(Q36577223)

15 August 2017

1 reference

title

Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial (English)

1 reference

15 August 2017

0 references

2

J Gregory Cairncross

1 reference

15 August 2017

Warren P Mason

1

1 reference

15 August 2017

publication date

1 December 2005

1 reference

Nature Clinical Practice Neurology

15 August 2017

published in

1 reference

15 August 2017

volume

1

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

88-95

1 reference

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Current and future developments in the use of temozolomide for the treatment of brain tumours

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

The Charing Cross Hospital experience with temozolomide in patients with gliomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Survival of human glioma cells treated with various combination of temozolomide and X-rays

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

A prospective study on glioblastoma in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Recent developments in the molecular characterization and treatment of oligodendroglial tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0045

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0045

1 reference

15 August 2017

1 reference